Form 4: Myriad Genetics Executive Mark Verratti Reports Stock Transactions
SEC Form 4 Filing
Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units and tax obligations.
Summary
- Mark Verratti, Chief Commercial Officer of Myriad Genetics, filed a Form 4 detailing changes in beneficial ownership.
- On March 13, 2025, Verratti acquired 99,227 shares of common stock at $0, related to time-based restricted stock units.
- On March 14 and 15, 2025, Verratti disposed of 5,847 and 3,729 shares respectively at $10.07 per share to cover tax withholding obligations.
- Following these transactions, Verratti beneficially owns 391,686 shares of Myriad Genetics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
Key Dates
| Date | Description |
|---|---|
| 03/13/2025 | Acquisition of 99,227 shares of common stock. |
| 03/14/2025 | Disposal of 5,847 shares for tax withholding. |
| 03/15/2025 | Disposal of 3,729 shares for tax withholding. |
| 03/17/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.